Cargando…
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
During the COVID-19 pandemic, several repurposed drugs have been proposed to alleviate the major health effects of the disease. These drugs are often applied with analgesics or non-steroid anti-inflammatory compounds, and co-morbid patients may also be treated with anticancer, cholesterol-lowering,...
Autores principales: | Telbisz, Ágnes, Ambrus, Csilla, Mózner, Orsolya, Szabó, Edit, Várady, György, Bakos, Éva, Sarkadi, Balázs, Özvegy-Laczka, Csilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827085/ https://www.ncbi.nlm.nih.gov/pubmed/33435273 http://dx.doi.org/10.3390/pharmaceutics13010081 |
Ejemplares similares
-
Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics
por: Ambrus, Csilla, et al.
Publicado: (2021) -
Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023) -
Interactions of Mycotoxin Alternariol with Cytochrome P450 Enzymes and OATP Transporters
por: Fliszár-Nyúl, Eszter, et al.
Publicado: (2022) -
Organic Anion Transporting Polypeptide 3A1 (OATP3A1)-Gated Bio-Orthogonal Labeling of Intracellular Proteins
por: Németh, Krisztina, et al.
Publicado: (2023) -
Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1
por: Patik, Izabel, et al.
Publicado: (2018)